



Company Overview

CytoDyn is a publicly traded late stage biotechnology company developing innovative treatments for multiple therapeutic indications based on Leronlimab, a novel humanized monoclonal antibody targeting the CCR5 receptor. CCR5 appears to play a key role in the ability of HIV to enter and infect healthy T-cells. The CCR5 receptor also appears to be implicated in tumor metastasis and in immune-mediated illnesses, such as graft-vs-host disease (GvHD) and NASH.

[CytoDyn's CRO in Brazil Met with ANVISA to Modify CD16 Trial for Critically Ill COVID-19 Patients to Expedite Interim Analysis After 51 Patients, Potentially in 1Q2022](#)

Dec 8 2021, 8:44 AM EST

[CytoDyn Submits CMC \(Manufacturing\) Section of HIV BLA to FDA Under Previously Authorized Rolling Review; Last \(Clinical\) Section Will Complete Full BLA Submission](#)

Dec 1 2021, 8:00 AM EST

[CytoDyn's Chairman, CMO, and Head of Business Development Dr. Scott A. Kelly to Present at World Antiviral Congress 2021 Beginning Tomorrow](#)

Nov 29 2021, 4:27 PM EST

Stock Overview

Symbol	CYDY
Exchange	OTCQB
Market Cap	693.2m
Last Price	\$1.05
52-Week Range	\$0.99 - \$7.40

12/08/2021 03:59 PM EST

Management Team

Nader Z. Pourhassan, Ph.D.

Director, President and CEO

Scott A. Kelly, M.D.

Chief Medical Officer, Head of Business Development and Chairman of the Board

Nitya G. Ray, Ph.D.

Chief Operating Officer and Chief Technology Officer

Christopher Recknor, M.D.

Senior Executive VP of Clinical Operations

Antonio Migliarese, C.P.A.

Chief Financial Officer

CytoDyn Inc.

1111 Main Street
Suite 660
Vancouver, WA 98660

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.